ChanRx Collects New Venture Capital Investment
Tuesday, November 22, 2011 5:55:00 AM PDT | VentureDeal Staff
Garfield Heights, Ohio -- Biotechnology company ChanRx (no website) has received an undisclosed amount of series A financing, according to a company statement.
ChanRx is developing small molecule drugs to treat atrial fibrillation.
The investment was from Sante Ventures and company founder, Dr. Arthur Brown.
The company said it would use the financing to "further evaluate the safety and efficacy of its proprietary AFIB drug, vanoxerine."
Email Page | Print Page